Zura Bio (ZURA) Income from Continuing Operations (2022 - 2026)
Zura Bio's (ZURA) quarterly Income from Continuing Operations came in at 24223000.0 in Q1 2026, down 38.88% year-on-year from 39630200.36 in Q1 2025, and down 33.53% quarter-over-quarter from 18140000.0 in Q4 2025.
Zura Bio (ZURA) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Zura Bio's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 24223000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 38.88% year-over-year to 24223000.0 in Q1 2026; TTM through Mar 2026 was 76396000.0, a 277.06% decrease from a year earlier, with the FY2025 full-year figure at 55199000.0, down 412.24% from the prior year.
- Income from Continuing Operations slipped to 24223000.0 in Q1 2026 per ZURA's latest filing, from 18140000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 28212000.0 in Q4 2024 and bottomed at 34025000.0 in Q2 2023.
- The 5-year median for Income from Continuing Operations is 9795000.0 (2023), against an average of 10414529.41.
- Across the five-year window, Income from Continuing Operations plunged 3578.38% in 2023 and jumped 432.96% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 2234000.0 in 2022, then sank by 279.27% to 8473000.0 in 2023, then soared by 432.96% to 28212000.0 in 2024, then tumbled by 164.3% to 18140000.0 in 2025, then slumped by 33.53% to 24223000.0 in 2026.
- Per Business Quant, the three latest ZURA Income from Continuing Operations figures stand at 24223000.0 (Q1 2026), 18140000.0 (Q4 2025), and 18040000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Zura Bio | 593.66 Mn | 593.66 Mn | - | -24.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.22 Mn |
| Dec 31, 2025 | -18.14 Mn |
| Sep 30, 2025 | -18.04 Mn |
| Jun 30, 2025 | -15.99 Mn |
| Mar 31, 2025 | -17.44 Mn |
| Dec 31, 2024 | 28.21 Mn |
| Sep 30, 2024 | -20.70 Mn |
| Jun 30, 2024 | -10.33 Mn |
| Mar 31, 2024 | -7.75 Mn |
| Dec 31, 2023 | -8.47 Mn |
| Sep 30, 2023 | -8.27 Mn |
| Jun 30, 2023 | -34.03 Mn |
| Mar 31, 2023 | -9.80 Mn |
| Dec 31, 2022 | -2.23 Mn |
| Sep 30, 2022 | -1.10 Mn |
| Jun 30, 2022 | -925,000.00 |
| Mar 31, 2022 | -7.82 Mn |